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Objectives The purpose of this study is to compare the efficacy of the treatment strategies for in-stent restenosis (ISR) of
drug-eluting stents (DES) according to the morphologic pattern of restenosis.
Background Optimal treatment strategies for ISR within DES have not been adequately addressed yet.
Methods Patients with ISR of DES were randomized according to the lesion length to compare outcomes of sirolimus-
eluting stent (SES) versus cutting balloon angioplasty for focal type (10 mm) and SES versus everolimus-
eluting stent (EES) for diffuse type (10 mm). The primary endpoint was in-segment late loss at 9 months. Over-
all 162 patients, 96 with focal ISR and 66 with diffuse ISR, were enrolled.
Results In focal lesions, in-segment late loss was significantly higher in the cutting balloon group (n  48) than in the
SES group (n  48; 0.25 mm, interquartile range [IQR]: 0.01 to 0.68 mm vs. 0.06 mm, IQR: 0.08 to 0.17
mm; p  0.04). Consequently, in-segment restenosis rate tended to be higher in the cutting balloon group than
in the SES group (20.7% vs. 3.1%, p  0.06) with comparable incidences of the composite of death, myocardial
infarction, or target vessel revascularization at 12 months of clinical follow up (6.3% vs. 6.3%, p  0.99). In 66
cases of diffuse ISR, in-segment late loss (0.11 mm, IQR: 0.02 to 0.30 mm; vs. 0.00 mm, IQR: 0.08 to 0.25
mm; p  0.64), in-segment restenosis rate (5.0% vs. 14.3%, p  0.32), and the composite incidence of death,
myocardial infarction, or target lesion revascularization (9.6% vs. 8.8%, p  0.99) did not differ between SES
group (n  32) and EES group (n  34).
Conclusions For lesions of focal DES restenosis, repeat implantation of SES is more effective in reducing late luminal loss
and subsequent restenosis rate than cutting balloon angioplasty. For diffuse DES restenosis, implantation of SES
or EES is comparably effective in terms of angiographic and clinical outcomes. (J Am Coll Cardiol 2012;59:
1093–100) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.047Although drug-eluting stents (DES) have dramatically re-
duced the rates of restenosis compared with bare-metal
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accepted November 8, 2011.stents (BMS), in-stent restenosis (ISR) of DES still exists,
and it has become a clinically significant problem due to its
considerable prevalence in complex coronary lesions (1,2).
However, the optimal management strategy for DES reste-
nosis remains undefined because clinical investigations have
been hampered by the low incidence of DES restenosis.
Moreover, determining a generalized optimal treatment
strategy for DES restenosis is difficult because etiology is
diverse and prognosis is different according to the mor-
phologic pattern (3,4).
For the focal type ISR, cutting balloon angioplasty has
been regarded as an attractive option because of its conve-
nience, cost effectiveness, and safety in the era of BMS (5,6).
However, few studies to date have compared repeat DES
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angioplasty in the focal type DES
restenosis. Also, for the diffuse
type ISR, there have been no stud-
ies comparing the new generation
DES with the established first-
generation DES. Therefore, the
aim of this randomized clinical
trial was to elucidate the optimal
treatment option according to the
morphologic pattern of ISR within
DES; to compare the effectiveness
of cutting balloon (Boston Scien-
tific, Natick, Massachusetts) an-
gioplasty with sirolimus-eluting
stent (SES [Cypher Select, Cor-
dis, Johnson & Johnson, Miami
Lakes, Florida]) implantation for the focal restenosis, and to
compare the effectiveness of everolimus-eluting stent (EES
[XIENCE V, Abbott Vascular, Santa Clara, California]) with
SES implantation for the diffuse restenosis.
Methods
Study design and population. This prospective, random-
ized, open-label, multicenter study was performed at 7
centers in South Korea between July 2008 and March 2011.
The study protocol was approved by the institutional review
board at each participating center. All patients provided
written, informed consent for participation in this trial.
The eligible patients were consecutively enrolled with
stable angina or acute coronary syndrome or inducible
ischemia in the presence of restenosis 50% diameter
stenosis in the stented segment with or without edge
involvement by quantitative coronary angiography. Patients
were excluded if they had acute ST-segment elevation
myocardial infarction (MI) necessitating primary percuta-
neous coronary intervention; severely compromised ventric-
ular dysfunction (ejection fraction 30%) or cardiogenic
shock; allergy to antiplatelet drugs, heparin, stainless steel,
contrast agents, everolimus or sirolimus; left main coronary
artery disease (defined as stenosis of 50%); chronic renal
failure (serum creatinine level2.0 mg/dl or dependence on
dialysis); terminal illness; elective surgery planned within 6
months after the procedure, necessitating discontinuation of
antiplatelet agent; participation in another coronary device
study or inability to follow the protocol.
Randomization, procedures, and adjunct drug therapy. Pa-
tients who met the inclusion and exclusion criteria were
randomized after diagnostic angiography and before angio-
plasty, with stratification by lesion length. Patients with ISR
lesions10 mm in length by visual estimation were enrolled
in the “focal ISR cohort” and were randomly assigned 1:1,
using an interactive web response system, to receive either
SES implantation or cutting balloon angioplasty. In con-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
IQR  interquartile range
ISR  in-stent restenosis
MI  myocardial infarction
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationtrast, patients with ISR length 10 mm were enrolled inthe “diffuse ISR cohort” and randomly allocated to SES or
EES implantation. The allocation sequence was computer-
generated and further stratified according to participating
center. Patients, but not investigators, were unaware of the
treatment assignment.
All procedures were performed with standard interven-
tional techniques. Cutting balloon dilation using cutting
balloons of 10 mm to 15 mm in length with the same or
0.25 mm to 0.5 mm larger diameter than the reference
vessel was attempted in all ISR lesions at the recommended
maximal pressure of 8 to 12 atm with or without additional
balloon inflation. Balloon angioplasty was regarded as suc-
cessful if the final residual stenosis was 30% with TIMI
(Thrombolysis In Myocardial Infarction) flow grade 3 and
absence of serious dissection. If the balloon angioplasty was
ultimately unsuccessful, additional stenting was attempted
at the operator’s discretion. The number and lengths of
stents to be implanted were at the operator’s discretion, but
the recommendation was to fully cover the restenotic lesion.
The choice of direct stenting or stenting after predilation
was at the operator’s discretion. It was recommended that all
procedures were guided by intravascular ultrasonography.
During the coronary intervention, patients received anti-
coagulation therapy with unfractionated heparin. Use of
adjunctive devices or glycoprotein IIb/IIIa inhibitors was at
the operator’s discretion. All patients were pretreated with
aspirin. Patients who were not already on a maintenance
dose of clopidogrel after the initial stent implantation were
also administered a loading dose of 300 mg of clopidogrel
within 12 h before the procedure. After intervention, patients
received aspirin (100 mg daily) indefinitely and clopidogrel
(75 mg daily) for at least 6 months after DES implantation.
Standard post-intervention care was recommended for all
patients (7).
Study endpoints and definitions. The primary endpoint
of this study was late luminal loss in the analysis segment 9
months after the index procedure. The secondary endpoints
were angiographic parameters including binary restenosis,
in-stent late loss at 9 months, and clinical outcomes includ-
ing death, MI, target lesion revascularization (TLR), target
vessel revascularization (TVR), stent thrombosis, and com-
posite of major adverse cardiac events, including death, MI,
and TVR within 12 months.
All deaths were considered to have been from cardiac
causes unless a noncardiac cause could be identified. Myo-
cardial infarction was defined as an elevation of creatine
kinase-myocardial band (CK-MB) or troponin to the upper
reference limit, and periprocedural MI was defined as an
elevation of CK-MB or troponin to at least 3 times the
upper reference limit during the first 48 h after percutaneous
coronary intervention (8). Target lesion revascularization
and TVR were defined as any revascularization procedure
involving target lesion and target vessel due to luminal
narrowing in the presence of symptoms or objective signs of
ischemia. Stent thrombosis was defined as definite or
probable thrombosis by the Academic Research Consortium
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of 30% of the vessel diameter after treatment.
Patient follow-up and data management. A 12-lead elec-
trocardiogram was obtained and CK and its MB isoenzyme
levels were measured before and at both 8 to 16 h and 18 to
24 h after the procedure. Clinical follow-up was scheduled
at 30 days, 6 months, and 12 months after the procedure
with monitoring of clinical status, rehospitalizations or
recatheterization, cardiac-related medications, and occur-
rence of adverse events. All eligible patients were asked to
return for an angiographic follow-up 9 months after the
procedure, or earlier if anginal symptoms occurred.
Clinical, angiographic outcome and procedural data were
collected using a dedicated electronic case report form by
specialized personnel at the clinical data management cen-
ter. All outcomes of interest were confirmed by source
documentation collected at each hospital and were centrally
adjudicated by an independent clinical events committee,
whose members were blinded to the assigned treatment. An
independent data and safety monitoring board reviewed the
data periodically to identify potential safety issues, but there
were no formal stopping rules.
Quantitative coronary angiography. Coronary angio-
grams were digitally recorded at baseline, immediately after
the procedure, and at follow-up, and were assessed off line
in the angiographic core laboratory (Asan Medical Center,
Seoul, Korea) using an automated edge-detection system
(CAAS V, Pie Medical Imaging, Maastricht, the Nether-
lands) by experienced assessors. All measurements were
performed on cineangiograms recorded after the intracoro-
nary administration of nitroglycerin. Standard qualitative
and quantitative analyses and definitions were used for
angiographic analysis (10). All quantitative angiographic
measurements were obtained within the stented segment
(in-stent) and over the entire segment including the stent
and its 5 mm proximal and distal margins (in-segment).
Angiographic variables included absolute lesion length, stent
length, reference vessel diameter, minimum lumen diame-
ter, percent diameter stenosis, binary restenosis rate, imme-
diate gain, late loss, and patterns of recurrent restenosis.
The reference diameter was determined by interpolation.
Binary restenosis was defined as percent diameter stenosis of
50% or greater on follow-up angiography, and patterns of
angiographic restenosis were quantitatively assessed with
the Mehran classification (11).
Statistical analysis. Sample size was calculated separately
for the focal and diffuse ISR cohorts with the same primary
endpoint of in-segment late loss. In the focal ISR cohort, we
assumed a mean in-segment late loss of 0.25  0.3 mm in
he SES group and 0.5  0.3 mm in the cutting balloon
ngioplasty group (12–15). Using 2-sided -level of 0.05
and a statistical power of 90%, expecting approximately 25%
of the patients would not receive follow-up angiography, a
total of 90 patients (n  45 per group) was needed. In the
diffuse ISR cohort, we assumed a mean in-segment late loss
of 0.5  0.3 mm in the SES group, and 0.2  0.3 mm in Ithe EES group (16,17). Using 2-sided -level of 0.05 and a
statistical power 90%, expecting approximately 25% of the
patients would not receive follow-up angiography, a total of
60 patients (n  30 per group) was needed to fulfill the
primary endpoint. Sample size was calculated with the use
of PASS software (NCSS, Kaysville, Utah).
All analyses were based on the intention-to-treat principle.
The statistician was blinded to treatment options in each
cohort during statistical analysis. All values are expressed as the
median (interquartile range [IQR]) for continuous variables or
as counts and percentages for categorical variables. Differences
in clinical, angiographic, procedural characteristics, and
outcomes between treatment groups were evaluated by the
Mann-Whitney U test for continuous variables and by the
hi-square test or Fisher’s exact test for categorical variables.
umulative frequency distribution curves in each group
ere compared with Kolmogorov-Smirnov test. To adjust
he baseline angiographic findings of each group, a multi-
ariable regression model was constructed using angio-
raphic covariates with p  0.1. To carry out the multivari-
ble regression analysis, the robust linear regression model
nd the generalized linear model with gamma distribution
ere fitted (18).
All statistical analyses were performed using SAS soft-
are, version 9.1 (SAS Institute, Cary, North Carolina) and
software, version 2.10.1, by a statistical analyst who was
naware of the type of stent implanted. A 2-sided p value of
0.05 was considered to indicate statistical significance.
esults
aseline characteristics and procedural results. In the
ocal cohort, a total of 96 patients was randomly assigned
o receive SES (n  48) or cutting balloon angioplasty
n  48). In the diffuse cohort, a total of 66 patients was
andomly assigned to receive SES (n  32) or EES
n  34). Table 1 shows the baseline clinical characteristics
f the study population. The lesion and procedural charac-
eristics are shown in Table 2. Most of clinical, lesion, and
rocedural characteristics were well matched between the 2
roups in both the focal and the diffuse ISR cohorts.
ngiographic outcomes. FOCAL ISR COHORT. Quantita-
ive angiographic results at baseline, post-procedure, and at
ollow-up in the focal cohort are shown in Tables 3 and 4.
evice success rates were 95.8% in the cutting balloon
roup and 100% in the SES group (p  0.16). Follow-up
ngiography was performed in 29 patients (60%) in the
utting balloon group and 32 patients (67%) in the SES
roup (p  0.58) at the median of 276 days (IQR: 261 to
08 days) in the SES group and 282 days (IQR: 271 to 339
ays) in the cutting balloon group (p  0.23) after the
rocedure, respectively. Between patients with and without
ngiographic follow-up, clinical or procedural characteristics
id not differ. Immediately after the procedure, in-segment
cute gain was similar between the 2 groups (SES 1.91 mm,
QR: 1.55 to 2.21 mm; vs. cutting balloon group 1.66 mm,
0
r
s
c
stent(s)
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endpoint, in-segment late loss was lower in the SES group
(0.06 mm, IQR: 0.08 to 0.17 mm]) than in the cutting
balloon group (0.25 mm, IQR: 0.01 to 0.68 mm; p 
.04). (Fig. 2) When the primary endpoint was fitted in the
egression model with angiographic covariates, the regres-
Baseline Clinical Characteristics of the PatientsTable 1 Baseline Clinical Characteristics of the Patients
Focal Lesion (<10 m
SES Group
(n  48)
CBA Group
(n  48)
Age, yrs 61.5 (55.3–66.8) 65.0 (57.3–70
Male 35 (72.9) 36 (75.0)
Diabetes mellitus 18 (37.5) 15 (31.2)
Hypertension 28 (58.3) 32 (66.7)
Hyperlipidemia 25 (52.1) 25 (52.1)
Smoking 16 (33.3) 23 (47.9)
Previous myocardial infarction 8 (16.7) 2 (4.2)
Left ventricular ejection fraction, % 60.0 (60.0–65.0) 60.0 (55.0–64
Multivessel disease 12 (25.0) 15 (31.2)
Clinical indication
Stable angina 32 (66.7) 37 (77.1)
Acute coronary syndrome 16 (31.3) 11 (22.9)
Values are median (IQR) or n (%).
CBA  cutting balloon angioplasty; EES  everolimus-eluting stent(s); SES  sirolimus-eluting
Baseline Lesion and Procedural CharacteristicsTable 2 Baseline Lesion and Procedural Characteristics
Focal Lesion (<
SES Group
(n  48)
CBA
(n 
Lesion characteristics
Target vessel
Left anterior descending 28 (58.3) 28 (5
Left circumflex 2 (4.2) 6 (1
Right coronary 18 (37.5) 14 (2
Bifurcation lesions 10 (20.8) 12 (2
Ostial lesion 6 (12.5) 2 (4
Calcification 2 (4.2) 4(8
Stent fracture 0
Angiographic pattern of restenosis*
Focal
IA (articulation or gap) 0
IB (margin) 13 (27.1) 7 (1
IC (focal body) 24 (50.0) 35 (7
ID (multifocal) 11 (22.9) 6 (1
Diffuse
II (intrastent) —
III (proliferative) —
IV (total occlusion) —
Procedural characteristics
Diameter of balloon or stent, mm 3.0 (3.0–3.5) 3.0 (2
Maximal pressure of balloon or stent, atm 15.0 (12.0–18.0) 10.0 (1
Glycoprotein IIb/IIIa antagonists 0
Number of stents 1.0 (1.0–1.0)
Length of stents, mm 18.0 (13.0–23.0)Values are n (%) or median (interquartile range). *Classified using the Mehran criteria (13).
NA  not available; other abbreviations as in Table 1.ion coefficient for in-segment late loss was 1.31 (95%
onfidence interval: 1.86 to 0.75; p  0.02) for cutting
balloon angioplasty compared with SES. These trends of
the result were not changed even after the angiographic
covariate adjustments in the multivariate regression analysis.
Accordingly, at follow-up, the SES group had larger in-
Diffuse Lesion (>10 mm)
p Value
SES Group
(n  32)
EES Group
(n  34) p Value
0.11 60.5 (54.3–67.0) 65.0 (54.7–69.0) 0.33
0.87 15 (46.9) 19 (55.9) 0.63
0.36 8 (25.0) 12 (35.3) 0.63
0.63 18 (56.3) 19 (55.8) 0.98
1.00 22 (66.8) 30 (75.0) 0.07
0.43 2 (6.3) 6 (17.6) 0.26
0.15 4 (12.5) 3 (8.8) 0.71
0.06 60.0 (57.8–61.0) 60.0 (55.0–64.3) 0.85
0.75 8 (25.0) 12 (35.3) 0.63
0.47 0.08
15 (46.8) 23 (67.6)
17 (53.1) 11 (32.4)
.
m) Diffuse Lesion (>10 mm)
p Value
SES Group
(n  32)
EES Group
(n  34) p Value
0.32 0.28
18 (56.3) 23 (67.6)
1 (3.1) 3 (8.8)
13 (40.6) 8 (23.5)
0.85 4 (12.5) 5 (14.7) 0.99
0.23 3 (9.4) 3 (8.8) 0.94
0.70 2 (6.3) 5 (14.7) 0.43
NA 0 0 NA
0.13
— —
— —
— —
— —
0.96
19 (59.4) 19 (55.9)
8 (25.0) 9 (26.5)
5 (15.6) 6 (17.6)
) 0.28 3.5 (3.0–3.5) 3.5 (3.0–3.5) 0.09
.0) 0.61 16.0 (12.0–19.5) 13.5 (10.0–18.0) 0.19
NA 0 0 NA
1.0 (1.0–1.75) 1.0 (1.0–2.0) 0.16
28.0 (23.0–33.0) 28.0 (23.0–28.0) 0.16m)
.0)
.0)10 m
Group
48)
8.3)
2.5)
9.2)
5.0)
.2)
.3)
0
0
4.6)
2.9)
2.5)
—
—
—
.9–3.5
0.0–14
0
—
—
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stenosis than the cutting balloon group. Subsequently, there
was tendency toward higher angiographic in-segment reste-
nosis rate in the cutting balloon group (20.7%) than in the
SES group (3.1%, p  0.06). (Table 4).
DIFFUSE ISR COHORT. In the diffuse cohort, baseline clin-
cal and angiographic characteristics were similar between
oth groups. Device success rates were 97.9% for SES and
5.7% for EES group (p  0.16). Follow-up angiography
as performed in 20 patients (62.5%) in the SES group and
1 patients (62.0%) in the EES group (p  0.91) at the
edian of 302 days (IQR: 274 to 384 days) in the SES
roup and 272 days (IQR: 219 to 286 days) in the EES
roup (p  0.17). Patients’ clinical and procedural charac-
eristics were not different between patients with and
Quantitative Angiographic Analysis Pre-Procedure and Post-ProcedTable 3 Quantitative Angiographic Analysis Pre-Procedure and
Focal Lesion (<10 mm)
SES Group
(n  48)
CBA Group
(n  48)
Before procedure
Lesion length, mm 8.63 (6.45–12.25) 7.45 (4.70–8.72
Reference vessel diameter, mm 3.18 (2.83–3.40) 2.93 (2.72–3.23
Minimal luminal diameter, mm 0.68 (0.50–0.86) 0.80 (0.53–1.00
Diameter stenosis, % 78.0 (70.3–83.0) 72.0 (63.0–81.0
Immediately after procedure
Minimal luminal diameter, mm
In segment 2.62 (2.23–2.84) 2.54 (2.04–2.79
In stent 2.78 (2.45–3.02) 2.68 (2.23–2.96
Diameter stenosis, %
In segment 6.0 (5.0–12.8) 7.0 (6.0–9.0)
In stent 4.0 (3.0–6.75) 5.0 (4.0–7.0)
Acute gain, mm
In segment 1.91 (1.55–2.21) 1.66 (1.37–2.05
In stent 2.09 (1.68–2.35) 1.81 (1.51–2.17
Values are median (IQR).
Abbreviations as in Table 1.
Quantitative Angiographic Analysis at 9-Month Follow-UpTable 4 Quantitative Angiographic Analysis at 9-Month Follow-
Focal Lesion (<10 mm
SES Group
(n  48)
CBA Group
(n  48)
Late luminal loss, mm
In segment 0.06 (0.08 to 0.17) 0.25 (0.01 to
In stent 0.02 (0.09 to 0.10) 0.30 (0.08 to 0.
Minimal luminal diameter, mm
In segment 2.37 (2.13 to 2.74) 2.13 (1.42 to 2.
In stent 2.57 (2.31 to 2.89) 2.08 (1.58 to 2.
Diameter stenosis, %
In segment 12.5 (4.5 to 24.5) 16.5 (8.3 to 42.
In stent 5.5 (1.0 to 16.0) 16.0 (6.0 to 37.
Angiographic restenosis
In segment 1 (3.1) 6 (20.7)
In stent 1 (3.1) 5 (17.2)Values are median (IQR) or n (%).
Abbreviations as in Table 1.ithout follow-up angiography. Immediately after the pro-
edure, in-segment acute gain was similar between the 2
roups (SES 1.43 mm, IQR: 0.96 to 1.97 mm; cutting
alloon group 1.48 mm, IQR: 0.99 to 2.32 mm; p  0.36).
Fig. 1) As a primary study endpoint, in-segment late
uminal loss were comparable between the SES group
0.11 mm, IQR: 0.02 to 0.30 mm) and the EES group
0.00 mm, IQR: 0.08 to 0.25 mm; p  0.64) (Fig. 2)
hen the primary endpoint was fitted in the regression
odel with the angiographic covariates, the regression
oefficient of EES for in-segment late loss was 0.81 (95%
onfidence interval: 0.40 to 2.02; p  0.50) compared
ith SES. These trends of the result were not changed even
fter adjustments in the multivariate regression analysis.
he rates of angiographic in-segment restenosis were 5.0%
-Procedure
Diffuse Lesion (>10 mm)
p Value
SES Group
(n  32)
EES Group
(n  34) p Value
0.03 22.24 (16.34–27.96) 22.46 (15.40–35.95) 0.89
0.05 3.19 (2.83–3.48) 3.43 (3.08–3.71) 0.08
0.09 0.94 (0.55–1.27) 0.75 (0.37–1.27) 0.43
0.09 71.5 (55.3–83.3) 72.0 (62.8–89.3) 0.19
0.42 2.30 (2.19–2.64) 2.43 (2.02–2.93) 0.65
0.30 2.78 (2.49–3.00) 2.87 (2.47–3.32) 0.65
0.40 18.0 (12.0–23.8) 18.0 (10.5–25.0) 0.36
0.03 6.0 (4.0–9.75) 7.0 (3.8–11.0) 0.55
0.10 1.43 (0.96–1.97) 1.48 (0.99–2.32) 0.36
0.05 1.93 (1.28–2.35) 1.89 (1.41–2.66) 0.32
Diffuse Lesion (>10 mm)
p Value
SES Group
(n  32)
EES Group
(n  34) p Value
0.04 0.11 (0.02 to 0.30) 0.00 (0.08 to 0.25) 0.64
0.001 0.13 (0.01 to 0.36) 0.07 (0.01 to 0.35) 0.88
0.04 2.17 (2.00 to 2.40) 2.30 (2.00 to 2.78) 0.45
0.002 2.58 (2.30 to 2.87) 2.71 (2.36 to 2.98) 0.58
0.04 25.0 (9.0 to 36.3) 18.0 (13.0 to 31.0) 0.88
0.001 16.0 (7.0 to 26.3) 18.0 (7.0 to 25.0) 0.81
0.06 1 (5.0) 3 (14.3) 0.32
0.10 1 (5.0) 3 (14.3) 0.32urePost
)
)
)
)
)
)
)
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(Table 4).
Clinical outcomes. Major clinical events during follow-up
re shown in Table 5. Clinical follow-up at 1 month and 12
onths were completed for all patients. In the focal cohort,
he incidence of clinical events including major adverse
ardiac events and individual endpoints of major adverse
ardiac events at 1 and 12 months did not differ between
he SES and the cutting balloon group. Three patients in
he cutting balloon group underwent repeated TLR, and 1
atient in the SES group had stent thrombosis during 12
onths. In the diffuse cohort, the incidence of clinical
vents at 1 and 12 months was also similar between the SES
nd EES groups. During 12 months of follow-up, in the
ES group, 1 patient died (18 days after procedure) of
ardiac causes, and 1 patient underwent repeated TLR. In
he EES group, 2 patients underwent repeat TLR, and
here was no death or stent thrombosis.
Figure 1 Cumulative Frequency Distribution Curves for In-Segm
(A) Focal in-stent restenosis (ISR). Blue line  sirolimus-eluting stent(s) (SES); br
SES; gray line  everolimus-eluting stent(s) (EES).
Figure 2 Cumulative Frequency Distribution Curves for In-Segm
(A) Focal in-stent restenosis (ISR). Blue line  sirolimus-eluting stent(s) (SES); br
SES; gray line  everolimus-eluting stent(s) (EES).Discussion
This randomized trial was designed to compare the efficacy
of the treatment strategies for ISR of DES according to the
morphologic pattern of restenosis, known as the most
important predictor of clinical outcomes. In the cases of
focal type DES restenosis, repeat implantation of SES
showed more effective trend for preventing late luminal loss
compared to cutting balloon angioplasty. However, in the cases
of diffuse type DES restenosis, SES and EES implantation
showed similar angiographic and clinical outcomes.
In the era of BMS, the angiographic pattern of restenosis
was prognostically important to predict TLR (11). Simi-
larly, the angiographic pattern of restenosis after DES
implantation has also been considered an important predic-
tor of long-term angiographic and clinical outcomes
(4,19,20). On the basis of these studies, it was proposed that
short DES placement or balloon angioplasty using the
cute Gain in Focal and Diffuse ISR Group
e  cutting balloon angioplasty. (B) Diffuse in-stent restenosis. Blue line 
ate Luminal Loss in Focal and Diffuse ISR Groups
e  cutting balloon angioplasty. (B) Diffuse in-stent restenosis. Blue line ent A
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March 20, 2012:1093–100 Treatment for Drug-Eluting Stent Restenosiscutting, scoring or drug-eluting balloon was recommended
for the treatment of focal type ISR. On the contrary, for
diffuse type of DES restenosis, repeat DES placement or
bypass surgery was recommended (3). However, there have
been few randomized studies comparing treatment modal-
ities according to angiographic patterns. We compared
cutting balloon angioplasty with repeat DES implantation
in the focal type of DES restenosis cohort because cutting
balloon may have better efficacy to extrude fibrous residual
neointimal plaque out of the stent strut and also have some
procedural advantages, such as use of fewer balloons, less
requirement for additional stenting and lower incidence of
balloon slippage compared with plain balloon angioplasty
(6,21). In our study of the focal restenosis cohort, late luminal
loss in the analysis segment, which was primary endpoint, was
lower in the SES group (0.06 mm, IQR: 0.08 to 0.17 mm)
han in the cutting balloon group (0.25 mm, IQR: 0.01 to
.68 mm) with numerically lower restenosis rate in the SES
roup (3.1%) compared to the cutting balloon group (20.7%).
his result indicates that repeat implantation of DES is still
ore effective than cutting balloon angioplasty in reducing
eointimal hyperplasia and preventing recurrent restenosis
ven for focal type DES restenosis.
The lack of benefit of cutting balloon angioplasty even for
ocal DES restenosis was contrasted with the results of
MS restenosis. For focal BMS restenosis, cutting balloon
ngioplasty showed comparable or more effective outcomes
ompared with BMS reimplantation or plain balloon an-
ioplasty (5,22,23). The reasons for the differential effec-
iveness of cutting balloon angioplasty in patients with DES
nd BMS restenosis are not clear. However, theoretically, it
ay be related with the different tissue components, and
Clinical Events at 1-Month and 12-Month Follow-UpTable 5 Clinical Events at 1-Month and 12-Month Follow-Up
Focal Lesion (<10 m
SES Group
(n  48)
CBA Group
(n  48)
Follow-up at 1 month
Death 0 0
Myocardial infarction 2 (4.3) 0
Death or myocardial infarction 2 (4.3) 0
Stent thrombosis 1 (2.1) 0
Target lesion revascularization 0 1 (2.1)
Target vessel revascularization 0 1 (2.1)
Major adverse cardiac events 2 (4.3) 1 (2.1)
Follow-up at 12 months
Death 0 0
Myocardial infarction 3 (6.3) 0
Death or myocardial infarction 3 (6.3) 0
Stent thrombosis 1 (2.1) 0
Target lesion revascularization 0 3 (6.3)
Target vessel revascularization 0 3 (6.3)
Major adverse cardiac events* 3 (6.3) 3 (6.3)
Values are n (%). *The pre-specified major adverse cardiac events were defined as a composite o
Abbreviations as in Tables 1 and 2.ubsequently different tissue reaction after balloon inflation, wetween DES and BMS restenosis. Studies using the patho-
ogic specimen of stent restenosis reported that neoatheroscle-
osis was more frequently observed in DES restenosis and
ccurred earlier than in BMS restenosis (24–26). It might be
onsidered that those pathologic characteristics of DES
estenosis could have more aggressive responses during
urgical cutting of neointima than BMS restenosis.
With regard to the diffuse type DES restenosis, there
ave been few studies comparing the first-generation
ES with new-generation DES. In this study, we dem-
nstrated statistically comparable late luminal loss and
ngiographic restenosis rate between the 2 different types
f DES. Previous studies have been considered repeat
ES treatment for diffuse DES restenosis is more effec-
ive compared to repeat paclitaxel-eluting stent implanta-
ion, plain balloon angioplasty and brachytherapy (27–29).
owever, we hypothesized that the reduced strut thickness and
thinner polymer coating in conjunction with improved
iocompatibility of polymer of the EES would have more
avorable effect on neointimal hyperplasia than SES. In con-
rast, however, in-segment late luminal loss at 9 months was
omparable between the SES group (0.11 mm, IQR:0.02 to
.30 mm) and the EES group (0.00 mm, IQR:0.08 to 0.25
m; p  0.64) with comparable angiographic and clinical
utcomes. Despite our small sample size, the favorable long-
erm outcomes we observed may have been due to the extensive
se of intravascular ultrasonography (SES 89.3%, EES 100%;
 0.09), even though we enrolled very long ISR lesions.
tudy limitations. First, because of lower angiographic
ollow-up rates, a follow-up bias may have been introduced
he results. However, because repeated angiographic
ollow-up of patients with DES restenosis is difficult in real
Diffuse Lesion (>10 mm)
p Value
SES Group
(n  32)
EES Group
(n  34) p Value
NA 1 (3.1) 0 0.49
0.26 1 (3.1) 1 (2.9) 1.00
0.26 2 (6.2) 1 (2.9) 0.61
0.50 0 0 NA
0.50 0 0 NA
0.50 0 0 NA
0.63 2 (6.2) 1 (2.9) 0.61
NA 1 (3.1) 0 0.49
0.13 1 (3.1) 1 (2.9) 1.00
0.13 2 (6.2) 1 (2.9) 0.61
0.48 0 0 NA
0.27 1 (3.1) 2 (5.8) 0.59
0.27 1 (3.1) 2 (5.8) 0.59
1.00 3 (9.6) 3 (8.8) 1.00
se death, myocardial infarction, and target vessel revascularization.m)orld settings, our results may at least stand for the actual
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Treatment for Drug-Eluting Stent Restenosis March 20, 2012:1093–100outcomes of patients. Second, despite power calculation, our
sample size was still underpowered to detect the minor
differences in the angiographic and clinical outcomes across
the different groups. However, this limitation may not
hamper the value of our study because a large-scale study
would be very difficult because of the very low incidence of
DES restenosis. Third, we included the lesions depending
on the angiographic findings without consideration of the
ISR mechanism. Therefore, we cannot exclude the possi-
bility that the mechanical factors of restenosis significantly
contributed to the result, such as under-expansion or stent
fracture. Because of these limitations of our study, a collab-
orative, larger multicenter study is required to provide the
results of diverse treatment modalities of DES restenosis.
Conclusions
In the focal DES restenosis, repeat SES implantation is more
effective for reducing late loss and subsequent angiographic
restenosis than cutting balloon angioplasty. However, in the
diffuse type DES restenosis, the second-generation EES is not
more effective than the first-generation SES in improving
angiographic or clinical outcomes.
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